Modeling Ocular Developmental Diseases From 3D Cultures of Optic Vesicle Organoids Derived From hiPSCs of Patients With Ocular Malformations

Recruiting Observational Study
Eye Abnormalities
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
6 and older
Sex
Any
Study type
Observational
Participants needed
20 (estimated)
Sponsor
University Hospital, Toulouse · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Ocular morphogenesis is a complex process starting as early as the 4th week of embryonic life, involving interactions between varioustissues of different origin and conserved genes. Anomalies in ocular development , often of genetic origin, pose diagnostic and therapeutic challenges. Animal models are limited, so human-induced pluripotent stem cell (hiPSC)-derived optic vesicle containing brain or…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Affiliated with a social security scheme. * Patients with ocular malformations. * Signed informed consent obtained from the patient and/or their legal representatives. Exclusion Criteria: * Inability to understand the nature and objectives of the study and/or difficulties in…
Contacts

Julie Plaisancie, MD, PhD

0561779075

plaisancie.j@chu-toulouse.fr

CONTACT